

The outcome of *Annona Muricata* Leaf Extract on Glucose, Malondialdehyde levels and Total Antioxidant Status in Alloxan-Induced hyperglycaemia in Wistar Rats

Madu Japhet Olisekodiaka¹, Oluwakolade Akande Adeyooye², Chinonso Johnjude Nnamdi¹, Chris Igbeneghu³ and Anaelechi Jude Onuegbu¹

¹Department of Chemical Pathology, Faculty of Basic Clinical Sciences, Nnamdi Azikiwe University, Awka, Anambra State, Nigeria

²Department of Anatomy, Osun State University, Osun State, Nigeria

³Department of Medical Laboratory Sciences, Faculty of Basic Medical Sciences, Ladoke Akintola University of Technology, Ogbomosho, Oyo State, Nigeria

ARTICLE INFO

Citation: Madu Japhet Olisekodiaka, Oluwakolade Akande Adeyooye, Chinonso Johnjude Nnamdi, Chris Igbeneghu and Anaelechi Jude Onuegbu (2025). The outcome of *Annona Muricata* Leaf Extract on Glucose, Malondialdehyde levels and Total Antioxidant Status in Alloxan-Induced hyperglycaemia in Wistar Rats.

Microbiology Archives, an International Journal.

DOI: <https://doi.org/10.51470/MA.2025.7.2.32>

Received 28 May 2025

Revised 23 June 2025

Accepted 25 July 2025

Available Online August 22 2025

Corresponding Author: Chinonso Johnjude Nnamdi

E-Mail: cj.nnamdi@unizik.edu.ng

Copyright: © The Author(s) 2025. This article is Open Access under a Creative Commons Attribution 4.0 International License, allowing use, sharing, adaptation, and distribution with appropriate credit. License details: <http://creativecommons.org/licenses/by/4.0/>. Data is under the CC0 Public Domain Dedication (<http://creativecommons.org/publicdomain/zero/1.0/>) unless otherwise stated.

ABSTRACT

Background: This contemporary study was conducted to investigate the potential effects of *Annona muricata* aqueous leaf extract on serum glucose levels, malondialdehyde (MDA) concentration, and total antioxidant status (TAS) in alloxan-induced diabetic Wistar rats. *Annona muricata*, a member of the Annonaceae family, is a fruit tree widely distributed in tropical and subtropical regions and is known for its diverse traditional uses. Commonly referred to as soursop, graviola, or guanabana, previous studies have demonstrated its pharmacological activities, including anticancer, anticonvulsant, anti-arthritis, hepatoprotective, and antidiabetic properties.

Methods: Twenty (20) male Wistar rats divided into four groups; consisting of five rats each as follows: group 1 = rat pellet + water + alloxan + chlorpopromide, group 2 = rat pellet + water + alloxan + extract, group 3 = rat pellet + water + alloxan and group 4 = rat pellet + water, and rats in group 4 served as control. Hyperglycaemia was induced in Groups 1, 2 and 3 by intraperitoneal injection of alloxan. Blood samples were collected at baseline and by the end of 3 weeks of administration of aqueous leaf extract *Annona muricata*, another blood sample was collected. The samples were used for estimation of glucose, MDA

and TAS by standard spectrophotometric methods.

Results: The administration of alloxan to the test groups; B, C and D, resulted in hyperglycaemia, increased MDA levels and decreased TAS. A notable decrease ($p < 0.05$) was observed when the extract and chlorpopromide treated diabetic groups were compared with the untreated diabetic group. A significant decrease ($p < 0.05$) in elevated MDA levels was observed when extract and chlorpopromide treated diabetic groups were compared with the corresponding diabetic control group. Increase in the mean TAS of chlorpopromide and extract treated groups when compared with the untreated diabetic group and treated diabetic group was observed.

Conclusion: A decrease in glucose level suggests that, leaf extract *A. muricata* has hypoglycaemic effects on alloxan induced hyperglycaemia in rats. A decreased MDA level suggests a reduction in free radical generation, an increase in TAS may reflect the ability of the antioxidative system to combat free radical related oxidative stress, which has been implicated in the pathology of various diseases.

Keywords: Diabetes mellitus, *Annona muricata*, Malondialdehyde, Total Antioxidant Status.

1.0 Introduction

Diabetes mellitus is a chronic metabolic disease envisioned by increased levels of blood glucose, which not controlled or managed over time leads to serious damage to the eyes, kidneys, nerves, blood vessels, and heart, in Nigeria, a national survey conducted by the Non – Communicable Disease Expert Committee (NCDEC) of the Federal Ministry of Health [1] recorded a prevalence of 2.2% lowest of which was 0.5% in Plateau state and highest 7% in Lagos Island. The increase in prevalence of diabetes progressively has been linked to modifiable factors (lifestyle changes, physical activities, consumption of alcohol, cigarette smoking, overweight and obesity) and non-modifiable factors [1].

Diabetes is generally classified into two main types: Type I and Type II. Type I diabetes is an autoimmune disorder characterized by the destruction of pancreatic β -cells, resulting in an absolute insulin deficiency [2]. It accounts for approximately 5–10% of all diabetes cases and is the most common subtype diagnosed in individuals under 20 years of age. Type II diabetes arises from a combination of peripheral insulin resistance and an inadequate insulin secretory response by pancreatic β -cells, leading to a “relative insulin deficiency” [2,28]. While traditionally considered “adult-onset,” the prevalence of Type II diabetes among children and adolescents has been steadily increasing [3].

The primary clinical manifestation of diabetes, hyperglycemia, contributes to diabetic complications by altering vascular cellular metabolism, vascular matrix molecules, and circulatory lipoproteins [4]. Chronic hyperglycemia in diabetes mellitus leads to multiple biochemical disturbances, and oxidative stress is believed to play a significant role in both the symptoms and progression of the disease [5,37].

The increased generation of reactive oxygen species from diseases results to oxidative stress in cells and tissue in antioxidants defence potential [6,32], and several hypothesis have been proposed to explain the genesis of these radicals in diabetes mellitus.

The Total antioxidant Status (TAS) can be described as a role of dietary, enzymatic and systemic antioxidants which is therefore an indicator of an individual free radical load [7,38]. TAS which consist of both enzymatic and non-enzymatic antioxidant assessment, is usually aimed at measuring the balance between free radicals activity and the antioxidants defence system. Low TAS is a significant indicator of oxidative stress, such oxidative stress occurs, when there is an imbalance between the oxidants and antioxidants status at the systemic level [8,29]. Insulin dependent diabetes mellitus (type I) is managed with exogenous insulin [9,31] and non-insulin dependent diabetes mellitus (type II) is managed with oral hypoglycaemic agents like sulfonylurea and biguanides [10]. Sulfonylurea acts as insulin stimulants and enhances the function of insulin at the receptor site [11]. Examples of commonly used drugs for the treatment of diabetes include metformin, glibenclamide and chlorpromide.

However, different cultures have used various parts of many plants for the treatment of diseases [12] and this includes the plant *Annona muricata* (*A. muricata*) which is commonly found in West Africa. All aspects of the plant, bark; leaves; roots; fruits and seeds, are used in natural medicine preparations in the tropics [13]. Previous study [14] showed that *A. muricata* contains flavonoids, and antioxidant activities due to the presence of quercetin in the leaves and other morphological parts of the plant and that these chemical components may exert an antidiabetic effects.

The main active chemical component of *Annona muricata* is acetogenin which has been demonstrated to exert a high potency against various types of cancer cells *in vitro* [15]. Other biochemical elements such as lactones; isoquinoline; alkaloids; tannins; coumarins; flavonoids; saponins; stearic acid; myristic acid; ellagic acid; B, C vitamins; etc has been reported to be extracted from parts of *Annona muricata*, (root, bark, leave, fruit and seed) [14]. Therefore, this study was design to measure the possible effects of *Annona muricata* leaf extract on glucose concentration, malondialdehyde (MDA) and TAS in experimental animal.

2.0 Materials and Methods

2.1 Selection of animals

Twenty (20) healthy male Wistar albino rats, of average weight 150g, were obtained from the Animal house of Ladoke Akintola University of Technology, (LAUTECH) were used for the experiment. After a two weeks acclimatization period to ensure uniform nutritional status, the animals were assigned to 4 groups; consisting of 5 rats in each group as follows; Group 1= Rat pellet + water + alloxan + chlorpromide; group 2 = Rat pellet + water + alloxan + extract; group 3= Rat pellet + water + alloxan; and group 4 = Rat pellet + water. Groups; B, C and D were induced with alloxan, two days after, test groups; C and D were

treated with chlorpromide and soursop extract respectively for 2 weeks. The wooden cages were cleaned daily as well as the feed and water trough. All animals were taken care-of in accordance with the principle of laboratory animals care of the National Society of Medical Research [27]. The experiments lasted for a period of 4 weeks.

2.2 *Annona muricata* leaf extraction

Fresh mature leaves of the *Annona muricata* tree were harvested from a farm in Egbedore Local Government area, Osun state Nigeria. The matured leaves were spread singly on the laboratory bench and were allowed to dry for a period of two weeks before granulation. The dried leaves were granulated with mortar and pestle and then blended into powder. Leaves extract was prepared by dissolving 10g of granulated leaves in 100mls of distilled water. The solution was then placed in a magnetic field for exactly 2hrs while being agitated continuously using a magnetic stirrer. The solution was sieved using a piece of white muslin cloth into a clean beaker. The content was poured into clean Petri dishes and placed in the oven at 45°C for 72 hrs. 1.2grams of the extract was recovered. The extract was diluted at 10% concentration w/v. 10mg of the extract was weighed and dissolved into 10mls of water. It was shaken and allowed to dissolve completely. The doses administered per kg body weight were calculated with the formula below,

$$\text{Administered volume} = \frac{\text{Intended dose} \times \text{Body weight} \times \text{Concentration}}{1000}$$

2.3 Induction of Diabetes in animals

After an overnight fast, hyperglycaemia was induced in rats in groups 1, 2 and 3. This was done by the single dose (150 mg/kg body weight) injection of freshly prepared solution of alloxan monohydrate dissolved in saline. Hyperglycemia was assessed by estimating the blood glucose concentration, 48 hours after injection of alloxan.

2.4 Blood sample collection and Biochemical Analysis

Two millilitres (2ml) of blood was obtained from the tail vein of each of the animals after an overnight fast and was used for the determination of fasting blood glucose (FBG) level. The rats with blood glucose level above 260mg/dl were selected for the experimental study.

Determination of glucose level was by the glucose oxidase/peroxidase (GOD/POD) method [16]. The method of Stocks and Dormandy describe by Vani et al, was used to determine the level of malondialdehyde and TAS [17].

2.5 Statistical Analysis

Results were reported as Mean± standard deviation (SD). Mean values were statistically analyzed using Statistical Package for Social Sciences (SPSS). Statistical analysis was performed using ANOVA. Relationships between the means of variables were determined using Pearson's correlation coefficient. Results were regarded as significant at $p < 0.05$.

3.0 Results

As presented in table 1; mean glucose concentration of the test group; (120.05±3.36) and control group; (114.20±7.76) was normal before the induction of alloxan. After the induction of alloxan, the mean glucose concentration of the other three groups; B C and D (423.80±28.89) became higher than that of the control group; (114.20±7.76) with a statistical significance of, $*P < 0.05$. following 2-3 weeks administration of extract and known drug (chlorpromide), the result, showed a significant

reduction in the level of elevated mean glucose level of the test groups from (423.80±28.89) to (129.00±5.46).

Table 1: Shows Glucose Levels Before Alloxan, After Alloxan and After Extract Administration

| Groups | Baseline Before Alloxan | Hyperglycemic State | 3 Weeks After Extract Administration | F-Value | P-Value |
|---------|-------------------------|---------------------|--------------------------------------|---------|---------|
| A (n=5) | 114.20±7.76 | --- | --- | 8.821 | P>0.05 |
| B (n=5) | 118.20±9.41 | 409.40±51.94 | --- | 8.821 | *P<0.05 |
| C (n=5) | 127.90±5.0 | 468.40±46.19 | 138.90±9.15 | 8.821 | *P<0.05 |
| D (n=5) | 120.50±3.36 | 423.80±28.89 | 129.00±5.46 | 8.821 | *P<0.05 |

As depicted in table 2; there is no significant difference in the mean MDA concentration of all the groups at baseline. After the induction of alloxan, there was a significant increase in the mean MDA value from (2.99±0.24) to (4.38±0.33) with a statistical significance of p<0.05. following 2-3 weeks, after treatment with extract, there was a decrease in the mean MDA concentration and the mean difference was not statistically significant.

Table 2: Mean (±SD) of MDA at Baseline, Hyperglycaemic State and 2 Weeks after Administration of Extract

| Groups | Baseline Before Alloxan | Hyperglycemic State | 3 Weeks After Extract Administration | F-Value | P-Value |
|---------|-------------------------|---------------------|--------------------------------------|---------|---------|
| A (n=5) | 2.99±0.24 | --- | --- | 12.194 | P>0.05 |
| B (n=5) | 2.99±0.24 | 4.38±0.33 | --- | 12.194 | *P<0.05 |
| C (n=5) | 2.99±0.24 | 4.38±0.33 | 3.35±0.15 | 12.194 | P>0.05 |
| D (n=5) | 2.99±0.24 | 4.38±0.33 | 3.50±0.13 | 12.194 | P>0.05 |

As presented in table 3; there was no significant difference in the mean TAS of all d groups at baseline. After the induction of alloxan, there was a decrease in the mean TAS concentration of the test groups C and D (2.55±0.16) when compared with the control group (2.98±0.18). 2-3 weeks after treatment with extract, there was an increase in the mean TAS of groups C and D and the mean difference was not statistically significant.

Table 3: Shows Mean (±SD) Of TAS at Baseline, Hyperglycaemic State and 3 Weeks after Administration of Extract

| Groups | Hyperglycemic State | 3 Weeks After Extract Administration | F-Value | P-Value |
|---------|---------------------|--------------------------------------|---------|---------|
| A (n=5) | --- | --- | 1.758 | P>0.05 |
| B (n=5) | 2.55±0.16 | --- | 1.758 | P>0.05 |
| C (n=5) | 2.55±0.16 | 3.01±0.17 | 1.758 | P>0.05 |
| D (n=5) | 2.55±0.16 | 3.12±0.15 | 1.758 | P>0.05 |

4.0 Discussion

Results we obtained from this study showed an increase in serum glucose, in alloxan treated Wister Rats when analogize with the corresponding control animals. Single daily dose of extract from *Annona muricata* leaf, greatly reduced glucose concentration in diabetic induced rats which caused a remarkable increase in serum insulin level. In a previous experiment [14,18], Ojewole and colleagues, reported that increased glucose level observed in streptozotocin induced diabetic rats was also reduced after treatment with *Annona muricata* leaf extract[19]. Another study also reported a remarkable difference between blood glucose concentrations of *Annona muricata* treated rats and untreated hyperglycaemic group of rats [15,31]. This current data therefore; shows, treatment of diabetic induced Wister rats with leaf extract of *Annona muricata*, caused a marked reduction in hyperglycaemia, which suggests an increased activity of serum insulin level, this is in consonance with study by Sawant and Dongre[15]. The decrease in glucose level of diabetic induced rats, after extract administration might be attributed to its ability (leaf extract) to enhance plasma membrane activity, through increment of hepatic GSH levels. This results to interference with progression of lipid peroxidation activities[15,20]. The results of this study, also showed a significant increase in the levels of Malondialdehyde (MDA) of alloxan treated rats when compared with the control group. Treatment of group D. rats with *Annona muricata* leaf extract resulted to a significant decrease in elevated Malondialdehyde level of the diabetic induced rats. In a previous study, [14,21] reported a decrease in Malondialdehyde level when alloxan induced diabetic rats were treated with leaf extract of *Annona muricata*.

The marked decrease in the MDA levels of diabetic induced rats treated with *Annona muricata* extract, may suggests that the leaf extract has some antioxidant properties, which probably save the tissues from the damaging consequences caused by lipid peroxidation [22,35].

The results of this current study shows a reduction in the total antioxidant activity (TAS) of alloxan treated Wister rats when compared with corresponding control groups. Treatment of the diabetic induced Wister rats with leaf extract of *Annona muricata*, boosted the antioxidant activity of the rats by increasing the total antioxidant activity (TAS). In a previous study by Adewole and colleagues [23], a significant increase in antioxidant activity was reported when streptozotocin induced diabetic rats were treated with Quercetin, which is one of the major compounds present in *Annona muricata* plant [18]. However, the results of this study showed only a slight increase in total antioxidant activity (TAS) level, which may be due to the variation in the duration of the experiment. This study lasted for a period of 4 weeks while the study by Adewole et al, lasted for 6 weeks [23]. The increase in total antioxidant status of *Annona muricata* extract treated diabetic rats also suggests that antioxidant activity shields the tissues against the damaging consequences of oxidation [24,29].

Even-though, the specific mechanism of action on the different biochemical variables exacted by the leaf extract explained in this study, could not be confirmed due to limited funds, some earlier investigators [30,34] has depicted that compounds like tannins and other polyphenolic elements, for example (coumarins, flavonoids, triterpenoids, saponnins, quercetin) and plant secondary metabolites, possesses hypoglycemic, hypolipidemic, antioxidant, anti-inflammatory, with varied pharmacological and biochemical properties in numerous exploratory animal models[19,30,31]. *Annona muricata* is said to contain, ellagic acid; tannins; flavonoids; polyphenolic compounds; triterpenoids; β-sistosterol [25,26,29], it is therefore reasonable to hint that some constituents of *Annona muricata* (coumarins, flavonoids and triterpenoids) might be held accountable for the anti-diabetic and antioxidant properties of *Annona muricata*, which we observed with the plants leafaqueous extract" in this study.

4.1 Conclusion

leaf extracts of *Annona muricata* has proven to possess a wide spectrum of biochemical activities, it is a desired tropical tree, in which a rich array of biochemical investigations has been conducted.

It's a desired fount for the staple food industry, in addition of being an indigenous medicinal plant. The effects of *Annona muricata* leaf extracts are completely amazing, further research is crucial to elucidate all the elements contributing to this amazing effect and the threshold of these effects. In conclusion, our study demonstrated that alloxan treatment maybe associated with oxidative stress and leaf extract of *Annona muricata* may possesses hypoglycaemic properties, in addition to antioxidant activities, it being able to inhibit and/or prevent oxidative stress and related advanced glycation end products (AGEs) caused by hyperglycemia.

Declarations

Ethical Approval: Ethical approval was sought and obtained from the Ethics Committee of Ladok Akintola University of Technology (LAUTECH).

Data availability: The data generated in this study are available from the corresponding author upon reasonable request.

Funding: None.

Conflicts of Interest: The authors declare that there are no conflicts of interest.

Limitations: The limitations to our study include, Time and Funding.

Authors Contribution: OJM conceptualized and designed the study. OJM and AOA contributed to implementation of the project and revision of the manuscript. The authors were involved in the writing and revision of the manuscript. IC and OJA were involved in the sample analysis. OJM and NJC collected the samples.

Acknowledgement: The authors are grateful to the Ladok Akintola University of Technology (LAUTECH) for giving us the ethical clearance.

Consent to publications: The authors read, approved the final manuscript for publication and agree to be accountable for all aspects of the work.

Key

Group A (control group) = Rat pellet + water only =group 4
 Group B (diabetes control) = Rat pellet + water + alloxan =group 3
 Group C (test group) = Rat pellet + water + alloxan + chlorpromide =group 1
 Group D (test group) = Rat pellet + water + alloxan + extract =group 2
 Group C (test group) = Rat pellet + water + alloxan + chlorpromide =group 1
 Group D (test group) = Rat pellet + water + alloxan + extract =group 2
 Group B (diabetes control) = Rat pellet + water + alloxan =group 3
 Group A (control group) = Rat pellet + water only =group 4
 Group 1= Rat pellet + water + alloxan + chlorpromide, group 2 = Rat pellet + water + alloxan + extract, group 3= Rat pellet + water + alloxan and group 4 = Rat pellet + water

References

1. World Health Organization-Diabetes Fact Sheets, (2020).
2. Kumar V, Abass AK, Fausto N and Aster JC (2010). Pathologic Basis of Disease 8th Edition. Saunders Elsevier 1131-1146.
3. Pradeepa, R.; Mohan, V. Prevalence of type 2 diabetes and its complications in India and economic costs to the nation.(2017) Eur. J. Clin. Nutr. 71, 816–824. [CrossRef]

4. Kaiser, A.B.; Zhang, N.; Der Pluijm, W. Global prevalence of type 2 diabetes over the next ten years (2018–2028). Diabetes 2018, 67, 202. [CrossRef]
5. Kapuy, O.; Papp, D.; Vellai, T.; Bánhegyi, G.; Korcsmáros, T.(2018) Systems-level feedbacks of NRF2 controlling autophagy upon oxidative stress response. Antioxidants 2018, 7, 39. [CrossRef] [PubMed].
6. Adefegha, S.A.; Oyeleye, S.I.; Oboh, G. (2015). Distribution of Phenolic Contents, Antidiabetic Potentials, Antihypertensive Properties, and Antioxidative Effects of Soursop (*A. muricata* L.) Fruit Parts In Vitro. Biochem. Res. Int. 2015, 347673. [CrossRef]
7. Wiid I, Medmen T, Hoal E, Benade A and Van Helden P (2004). Total antioxidants levels are low during active diseases. *IUBMB Life*, 56(2) 101-6.
8. Guzel K, Ziyatdinova C, Budnicova V and Pogorel'tzev (2006). Determination of Total Antioxidants Capacity of Human Plasma. *Eurasian journal of Analytical Chemistry* 1(1): 1-12
9. Felig G, Bergman M and Felig C (1995). The Endocrine Pancreas: Diabetes Mellitus (3rd Edition), McGraw Hill: New York. Pg1107-1250
10. Ngemenya, M.N.; Asongana, R.; Zofou, D.; Ndip, R.A.; Itoe, L.O.; Babiaka, S.B. (2022). In Vitro Antibacterial Potential against MultidrugResistant Salmonella, Cytotoxicity, and Acute Biochemical Effects in Mice of *A. muricata* Leaf Extracts. Evid. Based Complement. Altern. Med. 2022, 3144684. [CrossRef]
11. Berg J Tymoezko J and Stryer I (2007). Biochemistry (6th Edition). Editors: Allen, T. Freeman Publishers: New York Pg. 622 623
12. Lawal, A.Z., Abdulrahim H.A., Iyanda, Y.A., Munirudeen I. and Sanni, A.A. (2022). Effects of ethyl acetate leaf extract of *Annona muricata* on some enzymes of carbohydrate metabolism in streptozotocin-induced diabetic wistar rats. Nigerian Journal of Biochemistry and Molecular Biology. 37(1), 87-92.
13. E Sovia, W Ratwita, D Wijayanti, DR Novianty. (2017). Hypoglycemic and hypolipidemic effects of *Annona muricata* L. leaf ethanol extract. Int J Pharm Pharm Sci 2017;9(3):170-174.
14. Miranda, N.C.; Araujo, E.C.B.; Justino, A.B.; Cariaco, Y.; Mota, C.M.; Costa-Nascimento, L.A.; Espindola, F.S.; Silva, N.M. (2021) Anti-Parasitic Activity of *A. muricata* L. Leaf Ethanolic Extract and Its Fractions against *Toxoplasma Gondii* in Vitro and in Vivo.J. Ethnopharmacol. 2021, 273, 114019. [CrossRef]
15. Sawant R, Dongre TP.(2014). Biochemical compositional analysis of *Annona muricata*: a miracle fruit's review. Int J Univers Pharm Bio Sci 2014;3:82–104.

16. Stocks J and Dormandy TL (1971). The autoxidation of red cell lipids induced by hydrogen peroxide. *British Journal of Haematology* 20:95-111
17. Vani T, Rajani M, Sarkar S and Shishoo C.J. (1997). Antioxidant properties of the ayurvedic formulation triphala and its constituents. *International Journal of Pharmacognosy* 35: 313-317.
18. Ojewole JAO (2005). Antinociceptive, Anti-Inflammatory and Anti-Diabetic Effects of *Bryophyllum Pinnatum* (Crassulaceae) Leaf Aqueous Extract. *Journal of Ethno-Pharmacology* 99:13-19
19. Chukwunonso Agu, K.; Eluehike, N.; Oseikhumen Ofeimun, R.; Abile, D.; Ideho, G.; Olukemi Ogedengbe, M.; Omozokpea Onose, P.; Olalekan Elekofehinti, O.(2019). Possible Anti-Diabetic Potentials of *A. muricata* (Soursop): Inhibition of α -Amylase and α -Glucosidase Activities. *Clin. Phytoscience* 2019, 5, 21. [CrossRef]
20. Adeyemi OD, Omobola AK, Adewole OS, Obutor EM and Adenowo TK (2009). Anti-Hyperglycaemic Activities of *Annona Muricata*. *African Journal of Traditional and Complement Alternative Medicine* 6(1): 62-69
21. Sokpe, A.; Mensah, M.L.K.; Koffuor, G.A.; Thomford, K.P.; Arthur, R.; Jibira, Y.; Baah, M.K.; Adedi, B.; Agbemenyah, H.Y. (2020). Hypotensive and Antihypertensive Properties and Safety for Use of *A. muricata* and *Persea Americana* and Their Combination Products. *Evid. Based Complement. Altern. Med.* 2020, 8833828. [CrossRef]
22. Adewole OS and Ojewole OA (2009). Protective Effects of *Annona Muricata* Aqueous Extract on Serum Lipid Profiles and Oxidative Stress in Hepatocytes and Streptozotocin Treated Diabetic Rats. *African Journal of Traditional and Complement Alternative Medicine*. 6(1): 30-41
23. Opara, P.O.; Enemor, V.H.A.; Eneh, F.U.; Emengaha, F.C. (2021), Blood Glucose—Lowering Potentials of *A. muricata* Leaf Extract in Alloxan—Induced Diabetic Rats. *Eur. J. Biol. Biotechnol.* 2021, 2, 106–113. [CrossRef]
24. Adewole OS, Ezekiel A, Caxton-Martin and Adewole OA (2007). Protective Effects of Quercetin on the Morphology of Pancreatic B-Cells of Streptozotocin Treated Diabetic Rats. *African Journal of Traditional and Complement Alternative Medicine* 4(1): 64-74.
25. Florence, N.T.; Benoit, M.Z.; Jonas, K. (2014). Antidiabetic and antioxidant effects of *Annona muricata* (Annonaceae), aqueous extract on streptozotocin-induced diabetic rats. *J. Ethnopharmacol.* 2014, 151, 784–790. [CrossRef] [PubMed]
26. Ahalya, B.; Shankar, K.R.; Kiranmayi, G.V.N.(2014). Exploration of anti-hyperglycemic and hypolipidemic activities of ethanolic extract of *Annona muricata* bark in alloxan induced diabetic rats. *Int. J. Pharm. Sci. Rev. Res.* 2014, 25, 21–27.
27. Fauaz, Grasielle, Adriana Regina Miranda, Cinthia Zanini Gomes, Lilia Coronato Courrol, Flávia Rodrigues de Oliveira Silva, Flávia Gomes de Gães Rocha, Nestor Schor, and Maria Helena Bellini. "Erythrocyte Protoporphyrin Fluorescence as a Potential Marker of Diabetes", *Applied Spectroscopy*, 2010.
28. Patrick Emeka Aba, Chioma Uchenna Nwaigwe, Flora Ogbonne Okwuagwu, Samuel Chukwuneke Udem, Isaac Uzoma Asuzu. "Effect of aqueous extract of *Hibiscus sabdariffa* on some biochemical parameters in alloxan-induced diabetic rats", *Comparative Clinical Pathology*, 2014.
29. Guzel Ziyatdinova, Herman Budnikov, Valery Pogorel'tzev. "Determination of Total Antioxidant Capacity of Human Plasma from Patients with Lung Diseases Using Constant-Current Coulometry", *Eurasian Journal of Analytical Chemistry*, 2006.
30. Tunbosun Oladipo, Adeniyi Adebisi, Abiodun Adetomiwa, Oluwamayowa Oladipo, Olushola Adeleye, Johnny Olukunle. "Evaluation of spermatogenic activity of *Annona muricata* methanolic bark extract in Albino rats", *Egyptian Journal of Veterinary Sciences*, 2018.
31. "Diabetes mellitus and epithelial ovarian cancer in Chinese women: a retrospective cohort study", *European Journal of Gynaecological Oncology*, 2020.
32. F. Mougeot, J. Martinez-Padilla, J. D. Blount, L. Perez-Rodriguez, L. M. I. Webster, S. B. Pierny. "Oxidative stress and the effect of parasites on a carotenoid-based ornament", *Journal of Experimental Biology*, 2010.
33. Ali Çay, Mustafa İmamoğlu, Mesut A. Ünsal, Sevim Aydin, Ahmet Alver, Ahmet Akyol, Haluk Sarihan. "Does Anti-Oxidant Prophylaxis with Melatonin Prevent Adverse Outcomes Related to Increased Oxidative Stress Caused by Laparoscopy in Experimental Rat Model?", *Journal of Surgical Research*, 2006.
34. Benedicta Ayiedu Mensah, Henrietta E. Mensah-Brown, Frederica D. Partey, Christabel Addo et al. "Identifying risk factors for loss to follow-up in adults living with HIV in a high-burden district in Ghana", *BMC Public Health*, 2025.
35. Qiang Wan, Sang Luo, Qiwen Lu, Chengyan Guan, Hao Zhang, Zhiyan Deng. "Protective effects of puerarin on metabolic diseases: Emphasis on the therapeutical effects and the underlying molecular mechanisms", *Biomedicine & Pharmacotherapy*, 2024.
36. Nduka, Florence O., Ogugua, Victor N., Nwigwe, Juliet O., Nwaso, Chika B., Abdulrasheed, Momoh B.. "Effect of Aqueous Leaf Extract of *Eriosema psoraleoides* on Antihyperglycemic and Hypolipidemic Potentials in Alloxan-Induced Diabetic Rats", *Asian Journal of Research in Biochemistry*, 2019.
37. Siti Norliana Zubaidi, Pei Lou Wong, Wasim S.M. Qadi, Esraa Adnan Dawoud Dawoud et al. "Deciphering the mechanism of *Annona muricata* leaf extract in alloxan-nicotinamide-induced diabetic rat model with 1H-NMR-based metabolomics approach", *Journal of Pharmaceutical and Biomedical Analysis*, 2025.